Customize your JAMA Network experience by selecting one or more topics from the list below.
Tran DC, Colevas AD, Chang ALS. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma . JAMA Dermatol. 2017;153(1):92–94. doi:10.1001/jamadermatol.2016.3884
Cutaneous squamous cell carcinoma (CSCC) is one of the 2 most common types of human malignant tumors.1 Although most CSCCs are effectively treated with excision, recurrent disease near vital structures or metastasis can be challenging to treat. Currently, there is no accepted standard of care for unresectable or metastatic CSCCs, although platinum compounds, taxanes, and fluorouracil are commonly used. Recently, 2 reports of CSCC cases treated with programmed cell death 1 (PD-1) inhibitors have been published but contain limited follow-up times (<7 months).2,3 The safety profile of PD-1 inhibitors in CSCCs is also not well known. We present 6 consecutive cases of advanced CSCCs treated with PD-1 inhibitors, including an extended follow-up of 1 previously reported index case2 to 21 months of progression-free survival (PFS).
Create a personal account or sign in to: